Duchenne muscular dystrophy: Five trials to watch
The beginning to the year has been eventful in the Duchenne muscular dystrophy (DMD) space, with several trial readouts announced …
Post
-
-
Unmatched quality in pharmaceutical logistics: Why it matters
Ensuring the integrity of pharmaceutical products is one of the most complex challenges in global healthcare today. From temperature-sensitive biologics …
-
KalVista Pharmaceuticals enrols all subjects in hereditary angioedema drug trial
US-based biopharmaceutical company KalVista Pharmaceuticals has finished enrolling subjects in its KONFIDENT-KID trial of sebetralstat, an oral plasma kallikrein inhibitor …
-
Axsome’s Sunosi succeeds in Phase III ADHD trial
Axsome Therapeutics’ Phase III Focus trial investigating its attention-deficit hyperactivity disorder (ADHD) therapy, Sunosi (solriamfetol), has met its primary endpoint …
-
Cassava ends simufilam Alzheimer’s programme after second Phase III failure
Cassava Sciences has officially stopped the development of its investigational drug simufilam in Alzheimer’s disease after it failed to show …
-
Tiziana Life Sciences begins dosing in trial of therapy for multiple sclerosis
Biotechnology company Tiziana Life Sciences has begun dosing subjects in its placebo-controlled Phase II trial of foralumab, an intranasal fully …
-
Helicore doses first subject in Phase I trial of obesity treatment
US-based biopharmaceutical company Helicore Biopharma has dosed the first subject in a randomised, first-in-human Phase I trial of its humanised …
-
GSK and UK researchers plan to study Shingrix and dementia risk reduction link
GSK is collaborating with the UK Dementia Research Institute (UK DRI) and Health Data Research UK (HDR UK) to investigate …
-
Mural Oncology’s Phase III ovarian cancer trial failure knocks stock by 57%
Mural Oncology is discontinuing the development of nemvaleukin alfa in ovarian cancer after a Phase III trial failed to improve …
-
Early access programs for rare disease drugs in Europe: What you need to know
We’ve all seen the statistics – over 7,000 rare diseases, and only 5% have any approved treatments. It’s a situation …
-
Entrada gains UK MHRA authorisation to start Phase I/II trial of DMD treatment
Entrada Therapeutics has secured authorisation from the UK Medicines and Healthcare Products Regulatory Agency (MHRA) and Research Ethics Committee to …
-
Ractigen’s RAG-01 shows potential in treating non-muscle invasive bladder cancer
Ractigen’s small activating RNA (saRNA) therapy, RAG-01, designed to treat non-muscle invasive bladder cancer (NMIBC) has shown early promise in …
-
Unity reports topline outcomes from trial of diabetic macular oedema therapy
Unity Biotechnology has reported topline outcomes from its randomised Phase IIb ASPIRE study of intravitreal UBX1325 for diabetic macular oedema. The …
-
Surrozen drops hepatitis drug after Phase I flop
Surrozen is dropping its sole clinical asset after the drug failed at Phase I, as the company considers a move …
-
FDA aligns with Imunon’s Phase III trial protocol for ovarian cancer treatment
Imunon has announced the alignment of the US Food and Drug Administration (FDA) with the Phase III OVATION 3 trial …
